The InVyomma Plus Diagnostic Test by RGCC is a comprehensive molecular diagnostic tool designed to analyze circulating tumor cells (CTCs) and cancer stem cells (CSCs) in the bloodstream. This test provides insights into the genetic, epigenetic, and proteomic profile of cancer, offering actionable data to guide personalized treatment strategies. Here are the primary features and components of the InVyomma Plus Diagnostic Test:

Key Features

1. Circulating Tumor Cells (CTCs) Analysis:
   • Detects and quantifies CTCs, which are markers of metastasis and tumor progression.
   • Provides a snapshot of the tumor burden and potential metastatic activity.
2. Cancer Stem Cell (CSC) Profiling:
   • Identifies CSCs, which are often resistant to standard therapies and linked to relapse and metastasis.
   • Offers insights into therapeutic strategies targeting these resilient cell populations.
3. Gene Expression and Mutation Analysis:
   • Evaluates genes involved in cancer development, progression, and drug resistance.
   • Identifies actionable genetic mutations and markers for targeted therapy.
4. Epigenetic Profiling:
   • Assesses changes in gene regulation mechanisms, such as DNA methylation and histone modification, that influence cancer behavior.
5. Proteomic Analysis:
   • Measures protein expressions and interactions critical to cancer growth and therapy response.
6. Chemo-Sensitivity and Drug Resistance Testing:
   • Tests the sensitivity of cancer cells to various chemotherapeutic agents.
   • Helps optimize treatment by avoiding drugs that cancer cells are resistant to.
7. Immunophenotyping:
   • Analyzes immune cell markers and interactions with cancer cells.
   • Aids in planning immunotherapy strategies.
8. Comprehensive Reporting:
   • The test provides a detailed report highlighting potential therapeutic targets, resistance mechanisms, and recommended interventions.

Applications

• Personalized Oncology: Tailors treatment plans based on the molecular profile of the patient’s cancer.
• Monitoring Treatment Efficacy: Tracks the effectiveness of ongoing therapies by observing changes in CTCs and CSCs levels.
• Early Detection and Prognosis: Offers prognostic information and aids in the early detection of cancer recurrence.
• Drug Development and Research: Useful in clinical trials and research settings to study cancer biology and therapeutic responses.

The InVyomma Plus Diagnostic Test is particularly valuable for physicians and oncologists seeking a detailed understanding of cancer's behavior in individual patients, allowing for truly personalized and precise care.